ATE234917T1 - Avirulente salmonella mikroben mit einer mutation in dem cdt gen und ihre verwendung - Google Patents

Avirulente salmonella mikroben mit einer mutation in dem cdt gen und ihre verwendung

Info

Publication number
ATE234917T1
ATE234917T1 AT92901722T AT92901722T ATE234917T1 AT E234917 T1 ATE234917 T1 AT E234917T1 AT 92901722 T AT92901722 T AT 92901722T AT 92901722 T AT92901722 T AT 92901722T AT E234917 T1 ATE234917 T1 AT E234917T1
Authority
AT
Austria
Prior art keywords
mutation
immunogenic compositions
invertebrate
vertebrate
microbe
Prior art date
Application number
AT92901722T
Other languages
English (en)
Inventor
Roy Curtiss Iii
Sandra M Kelly
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE234917T1 publication Critical patent/ATE234917T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92901722T 1990-11-09 1991-11-08 Avirulente salmonella mikroben mit einer mutation in dem cdt gen und ihre verwendung ATE234917T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61200190A 1990-11-09 1990-11-09
PCT/US1991/008376 WO1992008486A1 (en) 1990-11-09 1991-11-08 Avirulent microbes and uses therefor: salmonella typhi

Publications (1)

Publication Number Publication Date
ATE234917T1 true ATE234917T1 (de) 2003-04-15

Family

ID=24451304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92901722T ATE234917T1 (de) 1990-11-09 1991-11-08 Avirulente salmonella mikroben mit einer mutation in dem cdt gen und ihre verwendung

Country Status (14)

Country Link
EP (2) EP0556333B1 (de)
JP (2) JP3601602B2 (de)
CN (1) CN1063416A (de)
AT (1) ATE234917T1 (de)
AU (1) AU666108B2 (de)
CA (1) CA2095534C (de)
DE (1) DE69133219T2 (de)
DK (1) DK0556333T3 (de)
ES (1) ES2194837T3 (de)
IE (1) IE913912A1 (de)
IL (1) IL100010A (de)
NZ (1) NZ240538A (de)
WO (1) WO1992008486A1 (de)
ZA (1) ZA918876B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326425D0 (en) * 1993-12-24 1994-02-23 Secr Defence Vaccine compositions
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
US8465755B2 (en) 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
RU2707548C1 (ru) * 2019-01-24 2019-11-27 Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) Штамм бактерий salmonella enterica subsp. enterica serovar typhi b-8453 с устойчивостью низкого уровня к фторхинолонам, используемый в качестве контрольного штамма для фенотипических и молекулярных исследований при диагностике брюшного тифа
RU2759396C1 (ru) * 2020-12-22 2021-11-12 Федеральное государственное бюджетное учреждение "Всероссийский государственный Центр качества и стандартизации лекарственных средств для животных и кормов" (ФГБУ "ВГНКИ") Штамм бактерий salmonella enterica (вкшм-б-849м) в качестве контрольного штамма для микробиологических и молекулярно-генетических исследований в определении антибиотикорезистентности
WO2024254447A1 (en) * 2023-06-07 2024-12-12 University Of Georgia Research Foundation, Inc. Compositions and methods for a differential diagnostic for salmonella typhimurium infection in poultry

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
AU589114B2 (en) * 1984-02-01 1989-10-05 Enterovax Limited Genetically engineered bacteria useful as a vaccine
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
AU637969B2 (en) * 1987-10-07 1993-06-17 Washington University A method of maintaining a desired recombinant gene in a genetic population of cells
JPH04506000A (ja) * 1989-03-31 1992-10-22 ワシントン・ユニバーシティ 無毒性微生物類およびそれについての使用
DE69027313T2 (de) * 1989-03-31 1997-01-23 Univ Washington Impfstoffe enthaltende avirulente phop-type mikroorganismen
AU9094191A (en) * 1990-11-21 1992-06-25 Washington University Recombinant avirulent salmonella antifertility vaccines

Also Published As

Publication number Publication date
IE913912A1 (en) 1992-05-20
WO1992008486A1 (en) 1992-05-29
EP1323428A2 (de) 2003-07-02
DE69133219D1 (de) 2003-04-24
EP1323428A3 (de) 2003-09-17
EP0556333B1 (de) 2003-03-19
AU666108B2 (en) 1996-02-01
JP2004337175A (ja) 2004-12-02
AU9120491A (en) 1992-06-11
EP0556333A4 (de) 1994-10-12
ES2194837T3 (es) 2003-12-01
CA2095534C (en) 2002-09-17
IL100010A (en) 1998-02-08
IL100010A0 (en) 1992-08-18
DE69133219T2 (de) 2004-02-12
JPH06501849A (ja) 1994-03-03
EP0556333A1 (de) 1993-08-25
CA2095534A1 (en) 1992-05-10
DK0556333T3 (da) 2003-07-14
JP3601602B2 (ja) 2004-12-15
ZA918876B (en) 1992-08-26
NZ240538A (en) 1994-01-26
CN1063416A (zh) 1992-08-12

Similar Documents

Publication Publication Date Title
DE69133219D1 (de) Avirulente salmonella mikroben mit einer mutation in dem cdt gen und ihre verwendung
FI903154A0 (fi) Kimeriska glykoproteiner innehaollande immunogeniska segment av glykoproteiner av maenniskans respiratory syncytial-virus.
KR890701125A (ko) 무병원성 미생물 및 이의 용도
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
DE68915165D1 (de) Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
KR970707281A (ko) 풀리뉴클레오티드 결핵 백신(A polynucleotide tuberculosis vaccine)
NO924507D0 (no) Protein fra haemophilus influenzae
ATE471335T1 (de) Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
ES426215A1 (es) Procedimiento para preparar una vacuna de adenovirus bovi- nos vivos.
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
JPS5696692A (en) Novel influenza virus strain and influenza virus vaccine containing same
ES8105394A1 (es) Procedimiento para la preparacion de cepas mutantes para va-cunacion
AU8501191A (en) Cross-reactive influenza a immunization
DK569985D0 (da) Vaccine indeholdende inaktiveret infektioes fuglebronkitisvirus
Curtis et al. Avirulent microbes and uses thereof
Pai et al. A Comparison of the Subcutaneous and Intradermal Methods of Immunization with TAB Vaccine—An Experimental Study
Eigelsbach et al. Tularemia prophylaxis: New live vaccine strains
Khanna et al. Vaccination studies in simian malaria using MDP as an adjuvant immunomodulator

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0556333

Country of ref document: EP

REN Ceased due to non-payment of the annual fee